

A placebo-controlled trial of granulocyte colony-stimulating factor in ceftazidime-treated patients in septic shock due to melioidosis

Submission date
12/09/2005

Recruitment status
No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date
14/10/2005

Overall study status
Completed

☐ Statistical analysis plan

☒ Results

Last Edited
21/03/2013

Condition category
Infections and Infestations

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Allen Cheng

Contact details

C/O Wellcome Unit
Faculty of Tropical Medicine
420/6 Rajvithi Road
Bangkok
Thailand
10400
+66 (0)2 3549172
allencheng@ozemail.com.au

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

Study information

Scientific Title

Granulocyte colony-stimulating factor in ceftazidime-treated patients in septic shock due to melioidosis: a placebo-controlled double-blind prospective randomised trial

Study objectives

In Darwin, Australia, the mortality in patients with melioidosis with septic shock has fallen from 95% (20 of 21 patients) to 10% (2 of 21 patients) since the adoption of granulocyte colony-stimulating factor (G-CSF). The hypothesis tested by this prospective randomised trial is that G-CSF can reduce the mortality of melioidosis-associated severe sepsis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. The Ministry of Public Health, Royal Government of Thailand
2. The Human Research Ethics Committee of the Menzies School of Health Research, Australia

Study design

Double-blind, prospective, randomised trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Septic shock due to melioidosis

Interventions

Patients will be treated with ceftazidime (the antibiotic treatment of choice), and randomised to receive either placebo or Lenograstim (recombinant human granulocyte colony stimulating factor [rhG-CSF]) (Granocyte®-Chugai Pharmaceutical, Japan). Dose: 300 µg intravenous injection, once daily for three days.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Ceftazidime, lenograstim

Primary outcome measure

The primary outcome measures will be in-hospital mortality and 28 day mortality.

Secondary outcome measures

Secondary outcome measures will include the following:

1. Treatment failure: unfavourable outcome or changing the regimen using these criteria:
 - 1.1. Obvious worsening of clinical signs and symptoms after 72 hours of treatment such as lowering of blood pressure, deterioration of shock
 - 1.2. B. pseudomallei persistently cultured in blood after seven days of treatment
 - 1.3. Persistent fever and no obvious improvement in any clinical signs and symptoms after ten days of treatment in the presence of other proper management such as surgical drainage of pus or fluid collection
2. Fever clearance time
3. Adverse drug reactions
4. Sequential Organ Failure Assessment (SOFA) scores at day one, three, seven and ten
5. Time to resolution of shock
6. Duration of ventilation
7. Duration of hospitalisation
8. Neutrophil function before and after treatment

Overall study start date

01/06/2003

Completion date

01/11/2005

Eligibility**Key inclusion criteria**

1. Community acquired septic shock (must fulfil criteria for sepsis, shock and end-organ perfusion abnormalities), and melioidosis is suspected:
 - 1.1. Sepsis: Systemic Inflammatory Response Syndrome (SIRS): two or more of the following, clinically ascribed to infection:
 - 1.1.1. Fever: temperature more than 38°C or less than 36°C
 - 1.1.2. Tachycardia: heart rate more than 90 beats/min
 - 1.1.3. Tachypnoea: respiratory rate more than 20 breaths/min or arterial carbon dioxide pressure (PaCO₂) less than 32 mmHg or mechanical ventilation
 - 1.1.4. White cell count more than 12,000 cells/ml or less than 4,000 cells/ml or more than 10% band forms
 - 1.2. Shock: hypotension for more than one hour in absence of other causes of hypotension (e.g. anaesthesia or antihypertensive medication) despite adequate fluid challenge sufficient to restore circulating blood volume (systolic blood pressure less than 90 mmHg or fall of more than 40 mmHg from baseline or requirement for vasopressors/inotropes)
 - 1.3. Septic shock: sepsis with shock with markers of perfusion abnormalities that may include

one or more of:

- 1.3.1. Metabolic acidosis: pH less than 7.3 or base excess less than 5 or bicarbonate (HCO_3) less than 15 mmol/l or anion gap more than 20 mmol/l or lactate more than 4 mg/l
- 1.3.2. Respiratory dysfunction: mechanical ventilation or partial pressure of oxygen in arterial blood (PaO_2)/fraction of inspired oxygen (FiO_2) less than 300 or respiratory rate less than 5 or more than 49 breaths/min or PaCO_2 more than 50 mmHg or PaO_2 /partial pressure of oxygen in the alveoli (PAO_2) ratio less than 0.5
- 1.3.3. Renal dysfunction: oliguria less than 30 ml/hour for three hours, or oliguria less than 700 ml /24 hours or creatinine more than 3 mg/dl or renal replacement therapy
- 1.3.4. Altered mental status Glasgow Coma Score (GCS) less than 15
- 1.3.5. Liver dysfunction: bilirubin more than 6 mg/dl and prothrombin time (PT) more than four seconds above normal control
- 1.3.6. Coagulopathy: International Normalised Ratio (INR) more than 1.4
2. Community acquired septicaemia (less than 72 hours of hospitalisation)
3. Patients who have received antibiotics prior to presentation are eligible
4. No known hypersensitivity to G-CSF
5. Aged more than 14 years, either sex
6. Need hospitalisation and intravenous antibiotic administration
7. Willingness to participate in the study and written, informed consent obtained from the patient

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

60

Key exclusion criteria

1. Known haematological malignancy, myelodysplasia or congenital neutropaenia
2. Febrile neutropaenia
3. Pregnant or lactating women
4. Known hypersensitivity to G-CSF
5. Patients not expected to remain in hospital for treatment
6. Known objection to participation in study
7. Patients who have previously been enrolled or who have received G-CSF within the past month
8. Patients with community-acquired sepsis with cultures positive for other organisms

Date of first enrolment

01/06/2003

Date of final enrolment

01/11/2005

Locations

Countries of recruitment

Thailand

Study participating centre

C/O Wellcome Unit

Bangkok

Thailand

10400

Sponsor information

Organisation

University of Oxford (UK)

Sponsor details

CCVTM

Churchill Hospital

Old Road

Headington

Oxford

England

United Kingdom

OX3 7LJ

+44 (0)1865 857433

ccvtm@clinical-medicine.oxford.ac.uk

Sponsor type

University/education

Website

http://www.jr2.ox.ac.uk/ndm/Tropical_Medicine

ROR

<https://ror.org/052gg0110>

Funder(s)

Funder type

Charity

Funder Name

The Wellcome Trust (UK) (grant ref: 077166)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2007		Yes	No